0000000001263732

AUTHOR

M Rendina

showing 4 related works from this author

AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

2016

After the first successful pregnancy in a liver transplant recipient in 1978, much evidence has accumulated on the course, outcomes and management strategies of pregnancy following liver transplantation. Generally, liver transplantation restores sexual function and fertility as early as a few months after transplant. Considering that one third of all liver transplant recipients are women, that approximately one-third of them are of reproductive age (18-49 years), and that 15% of female liver transplant recipients are paediatric patients who have a >70% probability of reaching reproductive age, the issue of pregnancy after liver transplantation is rather relevant, and obstetricians, paedi…

Risk AssessmentFertility; Immunosuppression; Liver transplantation; PregnancyImmunosuppressive AgentPregnancyMedicalFertility; Immunosuppression; Liver transplantation; Pregnancy; Hepatology; GastroenterologyHumansFertility; Immunosuppression; Liver transplantation; Pregnancy; Gastroenterology; HepatologyObstetric Labor ComplicationSocieties MedicalLiver transplantationHepatologyPostpartum PeriodPregnancy OutcomeGastroenterologyFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy OutcomeFertility; Immunosuppression; Liver transplantation; Pregnancy; Contraception; Female; Fertility; Gastroenterology; Humans; Italy; Obstetric Labor Complications; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Risk Assessment; Societies Medical; Immunosuppressive Agents; Liver Transplantation; Pregnancy Outcome; Hepatology; GastroenterologyPregnancy ComplicationObstetric Labor ComplicationsPregnancy ComplicationsContraceptionFertilitysurgical procedures operativeItalyPractice Guidelines as TopicFemaleSocietiesImmunosuppressive AgentsImmunosuppressionHuman
researchProduct

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver

2012

Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a h…

Liver CirrhosisMaleAGED PATIENTS; EPIDEMIOLOGY; HCV INFECTION; LIVER DISEASES; ANTI-VIRAL TREATMENTEpidemiologyCross-sectional studyHepacivirusLIVER DISEASESmedicine.disease_causeLiver disease80 and overPrevalenceEPIDEMIOLOGYChronicAged patientsAged 80 and overeducation.field_of_studyhepatitis c elderly italyAge FactorsHCV INFECTIONGastroenterologyliver diseases; hepatitis c elderly italy; hcv infection; epidemiology; aged patientsAlanine TransaminaseHepatitis CViral LoadAGED PATIENTSHepatitis CHCV infectionItalyHCVAged patients; Epidemiology; HCV infection; Liver diseasesPopulation studyFemaleViral loadmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusPopulationgeriatricAntiviral AgentsInternal medicinemedicineHumanseducationSettore MED/42 - IGIENE GENERALE E APPLICATALiver diseasesAgedHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C ChronicHepatitis C AntibodiesHepatologymedicine.diseaseSurgeryCross-Sectional StudiesAged patients; Epidemiology; HCV infection; Liver diseases; Age Factors; Aged; Aged 80 and over; Alanine Transaminase; Antiviral Agents; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Male; Prevalence; Viral Load; Gastroenterology; HepatologyANTI-VIRAL TREATMENTbusiness
researchProduct

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct